Deciphera Pharmaceuticals, Inc.
(NASDAQ : DCPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.45%185.151.2%$602.67m
CELGCelgene Corporation
-0.43%78.801.2%$532.62m
GILDGilead Sciences, Inc.
-0.63%71.070.9%$518.63m
BIIBBiogen Inc.
-0.44%296.041.2%$437.32m
NKTRNektar Therapeutics
-5.39%52.855.6%$412.99m
SRPTSarepta Therapeutics, Inc.
-6.23%140.3316.6%$356.37m
VRTXVertex Pharmaceuticals Incorporated
1.67%159.191.9%$269.27m
REGNRegeneron Pharmaceuticals, Inc.
0.89%331.972.6%$248.01m
ILMNIllumina, Inc.
-1.19%282.653.5%$212.82m
BLUEBluebird Bio, Inc.
-9.85%168.9015.7%$194.29m
EXASExact Sciences Corporation
-3.62%66.3325.4%$180.98m
AAgilent Technologies, Inc.
-0.40%62.791.5%$178.44m
ALXNAlexion Pharmaceuticals, Inc.
1.40%127.572.0%$159.93m
BMRNBioMarin Pharmaceutical Inc.
0.61%99.034.4%$141.99m
INCYIncyte Corporation
2.12%74.032.5%$133.28m

Company Profile

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.